RESEARCH ALLIANCE CORPORATION IV ANNOUNCES PRICING OF $75 MILLION INITIAL PUBLIC OFFERING

Rhea-AI Summary

Research Alliance Corporation IV (Nasdaq: RACD), a special purpose acquisition company sponsored by an affiliate of RA Capital Management, priced its $75 million initial public offering of 7,500,000 Class A ordinary shares at $10.00 per share. The shares are expected to begin trading on the Nasdaq Capital Market under the ticker “RACD” on July 13, 2026, with closing anticipated on July 14, 2026, subject to customary conditions.

The company is a blank check entity formed to pursue a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination, with an intended focus on healthcare and healthcare-related industries. Leerink Partners is acting as sole bookrunning manager, and multiple institutional investors participated. The SEC declared the registration statement effective on July 10, 2026.

Positive

• $75 million IPO priced via 7,500,000 shares at $10.00 each
• Listing on Nasdaq Capital Market under ticker RACD on July 13, 2026
• Registration statement declared effective by the SEC on July 10, 2026
• Backed by affiliate of RA Capital Management with defined healthcare focus

Negative

• None.

News Explained

The IPO is priced, not yet closed; completion would add 7,500,000 Class A shares and reduce existing ownership percentages absent offsetting changes.

On July 13, 2026, Research Alliance Corporation IV priced a $75 million IPO of 7,500,000 Class A ordinary shares at $10.00 each and said it expects closing on July 14, 2026, subject to customary closing conditions. If the closing occurs, the offering would add those Class A shares to the total share count, which can reduce an existing holder’s percentage ownership absent offsetting changes; the release does not disclose proceeds use.

The company describes itself as a special purpose acquisition company, or blank check company, formed to pursue a merger, acquisition, reorganization or similar business combination. It says the shares will begin trading on Nasdaq under the ticker RACD on July 13, 2026.

The release provides the share count and price but no dilution percentage, use-of-proceeds detail, or conversion mechanics, so it does not quantify the resulting ownership change or cash application.

The next disclosed milestone is the expected July 14, 2026 closing, which remains subject to customary closing conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, July 13, 2026 /PRNewswire/ -- Research Alliance Corporation IV (the "Company"), a special purpose acquisition company, announced today the pricing of its initial public offering of 7,500,000 Class A ordinary shares at $10.00 per share. The shares will be listed on the Nasdaq Capital Market and trade under the ticker symbol "RACD" beginning July 13, 2026. The Company expects the offering to close on July 14, 2026, subject to customary closing conditions.

The Company, sponsored by an affiliate of RA Capital Management, L.P., is led by CEO Matthew Hammond, PhD, MBA and CBO/COO Henry Stusnick. The Company is a blank check company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. The Company may pursue an initial business combination in any business, industry, sector or geographical location, but the Company intends to focus its search on a target business in the healthcare or healthcare-related industries, where it believes the expertise of its management team will provide it with a competitive advantage in completing a successful initial business combination.

Leerink Partners is serving as the sole bookrunning manager for the offering.

The financing included participation from Adage Capital Partners LP, ADAR1 Capital, Affinity Asset Advisors, LLC, Braidwell LP, BVF Partners, Deep Track Capital, Eventide Asset Management, Great Point Partners, LLC, Janus Henderson Investors, Perceptive Advisors, SilverArc Capital, Sirenia Capital Management LP, Spruce Street Capital, TCGX, Trails Edge Capital Partners, Venrock Healthcare Capital Partners and other institutional investors.

The offering is being made only by means of a prospectus. When available, copies of the prospectus may be obtained from: Leerink Partners LLC, Attn: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525 ext. 6105, or by email at syndicate@leerink.com.

A registration statement relating to the securities was declared effective by the U.S. Securities and Exchange Commission (the "SEC") on July 10, 2026. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

FORWARD-LOOKING STATEMENTS

This press release contains statements that constitute "forward-looking statements," including with respect to the proposed initial public offering and the anticipated use of the net proceeds from the offering. No assurance can be given that the offering discussed above will be completed on the terms described, or at all, or that the Company will ultimately complete a business combination transaction. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's registration statement and preliminary prospectus for the Company's offering filed with the SEC. Copies of these documents are available on the SEC's website, at www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

View original content:https://www.prnewswire.com/news-releases/research-alliance-corporation-iv-announces-pricing-of-75-million-initial-public-offering-302823826.html

SOURCE Research Alliance Corporation IV

FAQ

What is the size and pricing of the Research Alliance Corporation IV (RACD) IPO?

The Research Alliance Corporation IV IPO is sized at $75 million, with 7,500,000 Class A ordinary shares priced at $10.00 each. According to the company, this offering structure underpins its capital base for pursuing an initial business combination.

When will Research Alliance Corporation IV (RACD) start trading on Nasdaq?

Research Alliance Corporation IV shares are expected to begin trading on the Nasdaq Capital Market under ticker RACD on July 13, 2026. According to the company, the offering is expected to close on July 14, 2026, subject to customary conditions.

What type of company is Research Alliance Corporation IV (RACD) and what sector will it target?

Research Alliance Corporation IV is a special purpose acquisition company (SPAC) formed to complete a business combination. According to the company, it may target any sector but intends to focus its search on healthcare or healthcare-related industries.

Who is sponsoring Research Alliance Corporation IV (RACD) and who leads its management team?

Research Alliance Corporation IV is sponsored by an affiliate of RA Capital Management. According to the company, it is led by CEO Matthew Hammond, PhD, MBA, and CBO/COO Henry Stusnick, providing sector expertise for its planned business combination.

Who is the underwriter for the Research Alliance Corporation IV (RACD) IPO?

Leerink Partners is serving as the sole bookrunning manager for the RACD IPO. According to the company, the offering is being made only by means of a prospectus, which can be obtained directly from Leerink Partners using the provided contact details.

Has the SEC declared the Research Alliance Corporation IV (RACD) registration statement effective?

Yes, the registration statement for Research Alliance Corporation IV’s securities was declared effective by the SEC on July 10, 2026. According to the company, this effectiveness permits the IPO, subject to applicable state securities law requirements.

Which institutional investors participated in the Research Alliance Corporation IV (RACD) IPO financing?

According to the company, IPO financing included participation from institutional investors such as Adage Capital Partners, Perceptive Advisors, BVF Partners, Janus Henderson Investors, and others. This group also included multiple healthcare-focused investment firms and asset managers.